Research and Markets: Osteoarthritis Pain Therapeutics Pipeline Review, H2 2015 - 29 Companies & 50 Drug Profiles

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/cnkcg3/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • AbbVie Inc.
  • Addex Therapeutics Ltd
  • Afferent Pharmaceuticals, Inc.
  • Akron Molecules AG
  • Allergan Plc
  • Amgen Inc.
  • Ampio Pharmaceuticals, Inc.
  • AnaMar AB
  • Antibe Therapeutics, Inc.
  • AskAt Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bone Medical Limited
  • Centrexion Corporation
  • Convergence Pharmaceuticals Ltd.
  • Eli Lilly and Company
  • Elite Pharmaceuticals, Inc.
  • Flexion Therapeutics, Inc.
  • Grunenthal GmbH
  • Iroko Pharmaceuticals, LLC
  • Nektar Therapeutics
  • Nuvo Research Inc.
  • Pfizer Inc.
  • Phosphagenics Limited
  • Pozen, Inc.
  • Purdue Pharma L.P.
  • Regeneron Pharmaceuticals, Inc.
  • Rottapharm SpA

Drug Profiles

  • (lidocaine hydrochloride + tetracaine hydrochloride)
  • (naltrexone hydrochloride + oxycodone hydrochloride) SR
  • A-889425
  • AAT-008
  • ADX-71441
  • AF-219
  • AKR-202
  • AMAP-102
  • Ampion
  • AQU-010
  • AS-288640100
  • ATB-346
  • BI-1026706
  • calcitonin
  • capsaicin
  • cebranopadol
  • celecoxib
  • CGS-125
  • CR-4056
  • CRB-0022
  • CRB-0089
  • duloxetine hydrochloride DR
  • ELS-130
  • fasinumab
  • fulranumab
  • FX-005
  • grapiprant
  • ibuprofen
  • MEDI-7352
  • naproxen sodium
  • NEO-5024
  • NEO-6860
  • NKTR-181
  • OLT-1177
  • onabotulinumtoxin A

For more information visit http://www.researchandmarkets.com/research/cnkcg3/osteoarthritis

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System